People taking popular weight-loss and diabetes shots may be cutting their risk of a common cause of blindness by nearly a fifth, according to new research on GLP-1 drugs and eye health.
Quick Take
- A 2025 study found GLP-1 drugs linked to an 18% to 25% lower risk of dry age-related macular degeneration over one to three years.
- The same drug class showed a very different pattern for the wet, more dangerous form of the disease, with some studies reporting double the risk.
- Eye doctors and researchers call the data a “dichotomous” signal, protective in one form of macular degeneration and possibly risky in the other.
- Groups like the American Optometric Association now recommend eye exams before and during GLP-1 treatment.
What The New Research Actually Found
A cohort study published in JAMA Ophthalmology tracked patients using GLP-1 receptor agonists against those on other glucose-lowering drugs. Researchers found a real drop in nonneovascular, or dry, age-related macular degeneration. The risk reduction held at one year, two years, and three years, landing around 18% to 25% lower depending on the comparison group used. Dry macular degeneration is the slow, progressive version of the disease that damages central vision over time.
Other research backs up the dry-disease finding. A separate study comparing GLP-1 drugs to other weight-loss medications found a 53% lower hazard of nonexudative macular degeneration and a 39% lower hazard of any macular degeneration. Scientists think the drugs may calm inflammation and protect fragile retinal cells, the same anti-inflammatory action tied to their broader health benefits.
The Wet Macular Degeneration Problem
Here is where the story gets complicated. Separate research out of Canada found that diabetic patients on GLP-1 drugs faced more than twice the risk of developing neovascular, or wet, macular degeneration compared to those not taking the medication. Wet macular degeneration is rarer but far more aggressive. It happens when abnormal blood vessels leak fluid and blood into the macula, often causing rapid vision loss if untreated.
A commentary tied to that same research in the American Medical Association’s publication framed the dilemma bluntly. Should doctors prescribe these drugs because they lower dry disease risk, or pull back because they may raise wet disease risk? Reviewers have called this pattern “dichotomous,” meaning the same drug class appears to help one form of the disease while possibly harming the other.
Why Doctors Say It Is Too Early To Panic Or Celebrate
Several experts caution against reading too much into any single study. One review in a optometry publication noted that the wet-disease study didn’t screen out patients who already had early dry macular degeneration before starting treatment, which could skew the results. A broader review out of a Rome research team summed up the whole field simply: the evidence on macular degeneration “is conflicting, with signals of both benefit and risk”. That is not spin. It is the honest state of an emerging research area still working out which patients are actually at risk.
This kind of split result is common in early drug safety research. Large database studies can spot patterns fast, but they can’t always prove what caused them. Differences in patient age, diabetes status, and which comparison drug researchers used all shape the outcome. That is exactly what is happening here, and it is why groups like the American Optometric Association are not waiting for certainty before acting.
What Patients Should Actually Do
The American Optometric Association now recommends a full, dilated eye exam before starting a GLP-1 drug, especially for patients with diabetes or existing macular degeneration. A follow-up exam within a month of starting treatment is advised too. That is sound, practical advice regardless of which study ends up being right. Millions of Americans are now on these drugs for weight loss and diabetes, and a basic eye check costs little compared to catching a vision-threatening condition early.
None of this means patients should panic or quit their medication without talking to a doctor first. The absolute risk numbers involved are still small, and the drugs’ benefits for heart disease, diabetes, and weight loss are well documented. But eye health deserves a seat at that conversation, not an afterthought. Common sense says: get the exam, ask the questions, and let your doctor weigh your personal risk factors before deciding anything.
Sources:
mindbodygreen.com, pubmed.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov, ama-assn.org
